María Victoria
Mateos Manteca
Profesora Titular de Universidad
Heidelberg University
Heidelberg, AlemaniaPublicaciones en colaboración con investigadores/as de Heidelberg University (12)
2023
-
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT
Bone Marrow Transplantation, Vol. 58, Núm. 11, pp. 1182-1188
-
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
Nature Communications, Vol. 14, Núm. 1
2019
-
Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016
British Journal of Haematology
2018
-
Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network
Leukemia, Vol. 32, Núm. 7, pp. 1542-1560
2017
-
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology, Vol. 28, pp. iv52-iv61
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
-
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
The Lancet Oncology, Vol. 17, Núm. 8, pp. e328-e346
-
Multiple myeloma: practice patterns across Europe
British Journal of Haematology, Vol. 175, Núm. 1, pp. 66-76
-
Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group
Blood, Vol. 127, Núm. 24, pp. 2955-2962
2015
-
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051
2014
-
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
The Lancet Oncology, Vol. 15, Núm. 12, pp. e538-e548
2011
-
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. Melphalan-prednisone in the phase III VISTA trial in multiple myeloma
European Journal of Haematology, Vol. 86, Núm. 5, pp. 372-384